CD274 and metastatic melanoma: Clinically, anti-PD-L1 antibodies have been highly efficacious in the treatment of certain tumours, such as metastatic melanomas, ovarian cancers, oesophageal squamous cell carcinomas, and haematopoietic malignancies [68–72].